Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Mar 26;113(13):2888-94.
doi: 10.1182/blood-2008-07-168401. Epub 2008 Nov 10.

Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes

Marco Mielcarek  1 , Barry E Storer, Michael Boeckh, Paul A Carpenter, George B McDonald, H Joachim Deeg, Richard A Nash, Mary E D Flowers, Kristine Doney, Stephanie Lee, Kieren A Marr, Terry Furlong, Rainer Storb, Frederick R Appelbaum, Paul J Martin
Affiliations

Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes

Marco Mielcarek et al. Blood. .

Abstract

We hypothesized that initial treatment of acute graft-versus-host disease (GVHD) with low-dose glucocorticoids (prednisone-equivalent dose of 1 mg/kg per day) instead of standard-dose glucocorticoids (prednisone-equivalent dose of 2 mg/kg per day) does not compromise major transplantation outcomes. We retrospectively analyzed outcomes among 733 patients who received transplants between 2000 and 2005 according to initial treatment with low-dose (n=347) versus standard-dose (n=386) systemic glucocorticoids. The mean cumulative prednisone-equivalent doses at day 100 after starting treatment were 44 and 87 mg/kg for patients given low-dose and standard-dose glucocorticoids, respectively. Adjusted outcomes between the groups given low-dose versus standard-dose glucocorticoids were not statistically significantly different: overall mortality (hazard ratio [HR], 1.10; 95% confidence interval [CI], 0.9-1.4), relapse (HR, 1.22; 95% CI, 0.9-1.7), nonrelapse mortality (HR, 1.06; 95% CI, 0.8-1.5). The small number of patients with grades III/IV acute GVHD at onset precluded definitive conclusions for this subgroup. In multivariate analysis, the risks of invasive fungal infections (HR, 0.59; 95% CI, 0.3-1.0) and the duration of hospitalization (odds ratio, 0.62; 95% CI, 0.4-0.9) were reduced in the low-dose prednisone group. We conclude that initial treatment with low-dose glucocorticoids for patients with grades I-II GVHD did not compromise disease control or mortality and was associated with decreased toxicity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cumulative use of glucocorticoids among patients given either low-dose glucocorticoids (prednisone-equivalent dose of 1 mg/kg per day; dashed line) or standard-dose glucocorticoids (prednisone-equivalent dose 2 mg/kg per day; solid line) for initial treatment of acute GVHD. In this analysis, follow-up was censored when patients returned to the care of the referring physicians.
Figure 2
Figure 2
Major transplantation outcomes for patients with acute GVHD given either low-dose glucocorticoids (prednisone-equivalent dose of 1 mg/kg per day; dashed line) or standard-dose glucocorticoids (prednisone-equivalent dose of 2 mg/kg per day; solid line) for initial treatment of acute GVHD. Cumulative incidence of NRM (A) and recurrent malignancy (B), and Kaplan-Meier estimates of overall survival (C).
Figure 3
Figure 3
Cumulative incidence of secondary therapy among patients with acute GVHD initially given either low-dose glucocorticoids (prednisone-equivalent dose of 1 mg/kg per day) or standard-dose glucocorticoids (prednisone-equivalent dose of 2 mg/kg per day). (Left panel) Nonglucocorticoid secondary therapy. (Right panel) Increased glucocorticoid dose or nonglucocorticoid secondary therapy.
Figure 4
Figure 4
Cumulative incidence of invasive fungal infections among patients given either low-dose glucocorticoids (prednisone-equivalent dose of 1 mg/kg per day; dashed line) or standard-dose glucocorticoids (prednisone-equivalent dose of 2 mg/kg per day; solid line) for initial treatment of acute GVHD.
See this image and copyright information in PMC

Comment in

  • Where is the start line?
    MacMillan ML. MacMillan ML. Blood. 2009 Mar 26;113(13):2872-3. doi: 10.1182/blood-2008-12-192807. Blood. 2009. PMID: 19324908 No abstract available.

References

    1. Gratwohl A, Hermans J, Apperley J, et al. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia [review]. Blood. 1995;86:813–818. - PubMed
    1. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304. - PubMed
    1. Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood. 1990;75:1024–1030. - PubMed
    1. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007;7:340–352. - PubMed
    1. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314:729–735. - PubMed

Publication types